

Pre-proposal form SGF PPS Programme Immunology

1. Project details

Title of the project:
Main applicant*:
Institute:
Project duration:
Project keywords:
Requested budget:

* The main applicant is also the leader of the consortium. Researchers holding a Ph.D., employed by a public knowledge institute in the Netherlands can fulfil this role.

2. Consortium partners

Consortium Leader

Name:
Scientific expertise:
Institute:
Department:
Postal address:
Postal code:
City:
Email address:

Project applicants

Name:
Scientific expertise:
Institute:
Department:
Postal address:
Postal code:
City:
Email address:
Signature:

Name:
Scientific expertise:
Institute:
Department:
Postal address:
Postal code:
City:
E-mail address:
Signature:

Name:
Scientific expertise:
Institute:
Department:
Postal address:
Postal code:
City:
E-mail address:
Signature:

Financial officer

Name:
Scientific expertise:
Institute:
Department:
Postal address:
Postal code:
City:
E-mail address:
Signature:

3. Nederlandse Samenvatting voor leken (max. 2 A4)

Projectaanvragen worden mede beoordeeld door cliëntreferenten met een chronische aandoening. Zij vertegenwoordigen de Patiënten Adviesraad (of vergelijkbaar orgaan) van een gezondheidsfonds. Cliëntreferenten geven vanuit hun persoonlijke ervaringen advies over de aanvragen. Zorg voor een begrijpelijk en toegankelijke samenvatting. Maak mensen enthousiast voor het project!

Titel:
Hoofdaanvrager (instituut):
Duur project:
Aangevraagd bedrag:

- PPS-projectidee
- Aanleiding en achtergrond
- Doel van het onderzoek en onderzoeksvragen
- Plan van aanpak
- Relevantie voor verschillende aandoeningen
Op welke wijze sluit het onderzoek aan bij de behoeften van patiënten?
- Betrokkenheid patiënten, naasten of zorgverleners
- Risico's & Belasting studie-deelnemers^{*}
- Implementatie en maatschappelijke impact
De stappen die nodig zijn om het resultaat te implementeren en wat deelnemende consortiumpartners (onderzoekers en bedrijven) hieraan zullen bijdragen

* Alleen indien van toepassing

4. **Scientific abstract** (max. 250 words)

5. **A. Background and research questions** (A and B together max. 1500 words)
B. Approach and overview of the milestones
 including a general work plan, preferably sub-divided in work packages, and a (brief) dissemination plan to ensure the transfer of knowledge in order to maximize the impact of the proposed project.

6. **Please explain why this research is relevant for multiple diseases with an immunological component** (max 100 words)
 - Which groups of patients will benefit from your solution?
 - How many patients will possibly be reached?

7. **Please explain how patients are involved in the research (proposal)** (max 100 words)

8. **A. What will be the end results of the project?** (A and B together max. 250 words)
B. What is the expected Technology Readiness Level (TRL) of each of the project results (level of development/readiness to go to market)?

9. **What will be realized for patients by this project within the coming 5 to 10 years?** (max 100 words)

10. **PPP Allowance**
 PPP allowance can be used to co-finance a research project, in which at least four research institutes and at least two companies cooperate (a PPP consortium). Early involvement of other partners is an advantage. Please indicate which partners will work together in this consortium and how they will synergize (max 100 words).

Organisation	Type of organisation	Relevant expertise	Contact name	Email address

11. **Indicate in which category the consortium fits and please explain why the project is assigned to this category? Note that parts of the research can be assigned to different categories.**
 - A. Fundamental/Basic Research (max 75% PPP allowance)
 - B. Industrial research (max 50% PPP allowance)
 - C. Experimental development (max 25% PPP allowance)

Add your explanation here (max. 150 words):

For more information on the categories: <https://www.health-holland.com/public/downloads/tki-lsh/tki-lsh-match-call-2017-en.pdf>

12. Please give an estimation of the budget for the deployment of PPP allowance:

Type of research	Fundamental research	Industrial research	Experimental development
Maximum % PPP Allowance to be deployed	75%	50%	25%
Research organisation/ knowledge institution	Min 10%*	Min 15*	Min 20%*
Company - Large - SME	min. 15% - min. 10% in cash - min. 15%*	min. 35% - min. 20% in cash - min. 35%*	min. 55% - min. 30% in cash - min. 55%*

*May be fully in kind. In the case of SMEs, a cash contribution is encouraged

13. Intended start and end date:

The research project will need to start before January 1st, 2019 and must be completed before May 29, 2022.

Signed by:

Name:

Date:

Background information:

Each proposal must satisfy at least the following criteria:

- The proposal follows the TKI LSH Match regulations for public-private partnerships: <https://www.health-holland.com/public/downloads/tki-lsh/tki-lsh-match-call-2017-en.pdf>
- The research fits within the Health and Care Knowledge and Innovation Agenda 2018-2021 and is of a high quality.
- The consortium consists of at least two companies and at least four research organisations or knowledge institutions.
- The project covers fundamental research, industrial research or experimental development, or a combination thereof.
- The project will be realised at joint cost and risk and all consortium partners will make a substantive contribution to the project.
- The project must be completed before May 29, 2022
- Further information on the programme and criteria can be found in the programme text (separate document)